This is an incremental clinical progress update with no efficacy data or regulatory decision. Monitor for completion of dose-escalation phase and any subsequent efficacy readouts, which could move the stock. The $1M market cap implies high binary risk on trial outcomes.
Price Chart
Executive Summary
Clearmind Medicine announced it has dosed two additional participants in the fourth cohort of its Phase I/IIa trial for CMND-100 (alcohol use disorder), bringing the total treated to 20. The press release highlights continued dose escalation and a favorable safety profile, but provides no new financial data, efficacy results, or regulatory catalysts.
Key Facts
- 20 participants now treated across all cohorts in Phase I/IIa trial of CMND-100 for alcohol use disorder
- Fourth cohort dosing initiated at 160 mg following DSMB recommendation
- No serious adverse events reported across first three cohorts (18 participants)
- Trial sites include Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Centers
Financial Impact
No financial figures disclosed; clinical milestone with no revenue or cost impact reported
Risk Factors
- Clinical trial failure or safety signal in higher doses
- Dilution risk given $1M market cap and multiple outstanding F-3 shelf registrations
- No revenue or near-term commercialization path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-054785 |
| Document: ea029031102ex99-1.htm | 0001213900-26-054785 |
| Document: 0001213900-26-054785-index-headers.html | 0001213900-26-054785 |
| Document: 0001213900-26-054785-index.html | 0001213900-26-054785 |
| Document: 0001213900-26-054785.txt | 0001213900-26-054785 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $6.12 (+3.40%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $6.12 (−5.83%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers